DAMORA THERAPEUTICS INC
DMRANASDAQTrading Snapshot
- Day Range
- $30.39 – $30.74
- 52-Week Range
- $16.50 – $34.89
- Volume
- $2.42B
- Avg Volume
- $2.26B
- Shares Outstanding
- 61.5M
- Next Earnings
- Oct 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $607M
- Last Q Revenue
- $168M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-141.43
- Dividend Yield
- —
Why Investors Own DMRA
- ✓High-growth profile — revenue up -9.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About DAMORA THERAPEUTICS INC
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate
Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 85 percent increase over losses of $(2.60) per share from
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer half-life than a reference anti-mutCALR antibody, supporting its best-in-class potential -- WALTHAM, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology c
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Study Of DMR-001 To Treat Patients With Mutcalr-Driven Essential Thrombocythemia And Myelofibrosis
Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the initiation of the global Phase 1/1b CLARITY-101 clinical
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on August 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40
Wedbush analyst David Nierengarten maintains Damora Therapeutics (NASDAQ:DMRA) with a Outperform and raises the price target from $35 to $40.
This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.